Theratechnologies Shares Leap on FDA OK of Egrifta

WASHINGTON  Shares of Theratechnologies Inc. soared as high as 23 percent Thursday on word that the Canadian biotech won U.S. approval of Egrifta (tesamorelin) as the first and only therapy for HIV-associated lipodystrophy, a metabolic complication that affects patients taking antiretroviral therapies long term. (BioWorld Today)